COVID-19 Study Of Gilead’s Remdesivir Using Ebola-Style Adaptive Platform Trial
Executive Summary
First COVID-19 experimental treatment trial in US is a master protocol that echoes NIH’s Ebola treatment approach.
You may also be interested in...
US FDA's Ebola Drug Approvals Showcase Efficiencies With Master Protocols
Agency approved Regeneron’s monoclonal antibody cocktail Inmazeb and Ridgeback’s mAB Ebanga on data from a multi-arm, adaptive trial in which several investigational agents were independently compared to a control group. Efficacy for both drugs was demonstrated on a mortality endpoint, with lingering uncertainties to be addressed through postmarketing studies.
US FDA Welcomes Variety Of Phase II/III Trial Designs For COVID-19 Therapies, But With Standards
Final guidance on COVID-19 treatment development emphasizes need for clinical endpoints to reflect drug mechanism, patient population, clinical setting and fast-evolving standard of care – with a cautious embrace of platform and adaptive designs.
Gilead's Remdesivir Results Encouraging, Safety Brings Skepticism
Analysts see NIAID’s placebo-controlled data as more important than Gilead’s open-label data. Quick emergency use authorization by FDA is possible, but the US agency has not confirmed EUA.